QuidelOrtho (NASDAQ:QDEL) Issues FY 2025 Earnings Guidance

QuidelOrtho (NASDAQ:QDEL) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 2.000-2.150 for the period, compared to the consensus EPS estimate of 2.260. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on QDEL. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of QuidelOrtho in a research report on Wednesday, October 8th. Wall Street Zen downgraded shares of QuidelOrtho from a “buy” rating to a “hold” rating in a research note on Saturday, July 26th. Citigroup reaffirmed a “neutral” rating and set a $33.00 price objective (down from $40.00) on shares of QuidelOrtho in a research report on Tuesday, October 7th. UBS Group reduced their target price on QuidelOrtho from $29.00 to $26.00 and set a “neutral” rating on the stock in a report on Thursday, August 7th. Finally, Zacks Research cut QuidelOrtho from a “hold” rating to a “strong sell” rating in a research note on Monday, October 13th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $37.80.

QuidelOrtho Stock Up 0.9%

NASDAQ QDEL traded up $0.24 during trading hours on Wednesday, reaching $27.37. 1,856,407 shares of the company’s stock traded hands, compared to its average volume of 1,302,873. QuidelOrtho has a 52-week low of $22.05 and a 52-week high of $49.45. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.12 and a quick ratio of 0.62. The firm has a 50-day simple moving average of $28.45 and a 200 day simple moving average of $28.46. The firm has a market cap of $1.86 billion, a PE ratio of -4.19 and a beta of 0.35.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Wednesday, November 5th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.62 by $0.18. QuidelOrtho had a negative net margin of 16.10% and a positive return on equity of 5.29%. QuidelOrtho has set its FY 2025 guidance at 2.000-2.150 EPS. Sell-side analysts anticipate that QuidelOrtho will post 2.3 EPS for the current fiscal year.

Institutional Investors Weigh In On QuidelOrtho

Institutional investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its position in shares of QuidelOrtho by 250.7% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,230 shares of the company’s stock worth $93,000 after purchasing an additional 2,309 shares during the last quarter. Osaic Holdings Inc. grew its position in QuidelOrtho by 298.1% during the 2nd quarter. Osaic Holdings Inc. now owns 3,300 shares of the company’s stock valued at $95,000 after purchasing an additional 2,471 shares during the last quarter. State of Wyoming raised its holdings in QuidelOrtho by 230.5% in the second quarter. State of Wyoming now owns 4,524 shares of the company’s stock worth $130,000 after buying an additional 3,155 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of QuidelOrtho by 829.3% in the second quarter. Tower Research Capital LLC TRC now owns 5,297 shares of the company’s stock worth $153,000 after buying an additional 4,727 shares in the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of QuidelOrtho during the second quarter valued at approximately $271,000. 99.00% of the stock is owned by hedge funds and other institutional investors.

About QuidelOrtho

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.